Replies to post #218403 on Biotech Values

[DewDiligence]

MOR sells 9.55M ADSs@$25.04 in Nasdaq IPO:

https://www.morphosys.com/media-investors/media-center/morphosys-announces-pricing-of-initial-public-offering-of-american

MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development.

…In 2017, Tremfya (guselkumab), marketed by Janssen, became the first therapeutic antibody based on MorphoSys's proprietary technology to receive marketing approval for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada.

Each ADS is equivalent to 0.25 ordinary shares (i.e. MOR.F or MOR.DE shares).

*Assuming exercise of underwriter’s option.